Pharmaxi (შპს ფარმაქსი) — Georgia Financials

Georgia Financials

panel 2026-09-21Ask

Pharmaxi (შპს ფარმაქსი) — Georgia Financials

separate · GEL, thousands

Line item	2017	2018	2019	2020	2021	2022	2023	CAGR
	2,049	2,768	2,823	25,488	49,897	38,360	37,235	+62.1%
Total COGS	128	156	155	7,425	10,598	8,723	10,432	+108.2%
Gross Profit	1,921	2,612	2,668	18,063	39,299	29,637	26,803	+55.2%
Gross Margin	93.7%	94.4%	94.5%	70.9%	78.8%	77.3%	72.0%
Other Operating Income	0	0	0	0	0	0	38
	420	787	901	6,463	19,315	24,740	24,557	+97.0%
EBITDA	1,501	1,825	1,767	11,600	19,983	4,897	2,284	+7.2%
EBITDA Margin	73.3%	65.9%	62.6%	45.5%	40.0%	12.8%	6.1%
Total D&A	48	55	60	0	0	0	937	+63.8%
EBIT / Operating Income	1,453	1,770	1,708	11,600	19,983	4,897	1,347	-1.3%
Total Interest Income	0	151	221	355	0	0	26	-29.9%
Total Interest Expense	0	0	0	0	0	0	768
	0	20	1	4,286	1,040	691	417	nmf
Profit Before Tax	1,453	1,901	1,930	7,669	18,944	5,587	188	-28.9%
Total Income Tax	0	0	0	0	0	0	0
Net Profit / (Loss)	1,360	1,804	1,720	7,314	18,944	5,587	188	-28.1%
Net Margin	66.4%	65.2%	60.9%	28.7%	38.0%	14.6%	0.5%